EE155 Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-17A and IL-12/23 Targeted Therapies for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons.

Autor: Mestre-Ferrandiz, J.1 (AUTHOR), Navarro-Compán, V.2 (AUTHOR), Ivanova, Y3 (AUTHOR), González-Domínguez, A.3 (AUTHOR), Maratia, S4 (AUTHOR)
Zdroj: Value in Health. 2024 Supplement, Vol. 27 Issue 12, pS84-S84. 1p.
Databáze: Academic Search Ultimate
Externí odkaz: